摘要
目的总结手术切除Ⅰ-Ⅲ期胃癌的临床特点,探讨胃癌术后常规检测分子表皮生长因子受体1(HER1)、HER2、P53、血管内皮生长因子(VEGF)、拓扑异构酶IIα(TOPIIα)、Ki67、P糖蛋白(P170)的表达及对预后的影响。方法回顾性分析41例I-III期胃癌手术病例,综合临床、病理特征及术后7项常规分子标记物的免疫组织化学指标,对患者无疾病生存时间(DFS)采用SPSS 17.0软件包进行单因素及多因素分析。结果全部病例术后随访时间为36个月,中位随访期18个月,1年总生存率为95.12%,中位DFS为17个月,1年DFS生存率为70.59%。术后患者HER1、HER2、P53、P170、Ki67、VEGF和TOPIIα均有阳性表达,HER2、P53、VEGF和TOPIIα高表达DFS降低(P<0.05)。结论 HER2、P53、VEGF和TOPIIα阳性表达DFS降低。
Objective To investigate the expression of biomarker HER1、HER2、P53、VEGF、TOPIIα、Ki67 and P170,to explore their relationship to the prognosis of stage I-III Gastric Cancer（GC） patients post gastrectomy. Methods Clinical and pathological data as well as 7 immunohistological biomarkers listed above in 41 cases who had been diagnosed stage I-III GC and receivedgastrectomy were retrospectively analysed. We also analyzed the single/multiple factors involved on patients ′ disease free survival（DFS） time by using SPSS 17.0 statistical software. Results Of all the cases investigated the follow-up time after the surgery was 36 months,the median follow-up time was 18 months. The one-year survival rate was 95.12% with a median DFS 17 months,one-year DFS 70.59%. The expression of HER1,HER2,P53,P170,Ki67,VEGF and TOPIIα wer e positive in all cases,the over-expression of HER2,P53,VEGF and TOPIIα were positively-related with DFS decrease（p〈0.05,p〈0.01）. Conclusion DFS drop is significantly related to HER2,P53,VEGF and TOPIIα over-expression in tumor tissue.
出处
《中华保健医学杂志》
2015年第4期293-296,共4页
Chinese Journal of Health Care and Medicine
